LY-3540378
- Generic Name
- LY-3540378
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT06598631
- Locations
- 🇦🇺
Renal Research - Gosford, Gosford, New South Wales, Australia
🇨🇳Taian City Central Hospital, Taian, Shandong, China
🇺🇸Endocrine Associates, Houston, Texas, United States
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase 2
Terminated
- Conditions
- Heart FailureHeart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 335
- Registration Number
- NCT05592275
- Locations
- 🇺🇸
Pima Heart, Tucson, Arizona, United States
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸Pasadena Clinical Research, Pasadena, California, United States
A Study of LY3540378 in Healthy Participants
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 134
- Registration Number
- NCT04768855
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇸🇬Lilly Centre for Clinical Pharmacology, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath